Cytokine release syndrome (CRS) management — the tocilizumab-based treatment protocols now established as standard of care for CAR-T and bispecific antibody-induced CRS, representing the fastest-growing supportive care segment in oncology — creates the most clinically critical market dynamic, with the Cytokine Release Syndrome Management Market reflecting CRS management as the...